Kathleen K Schoemaker Net Worth

The estimated Net Worth of Kathleen K Schoemaker is at least 1.33 百万$ dollars as of 1 July 2013. Kathleen Schoemaker owns over 285,714 units of Zogenix Inc stock worth over 940,550$ and over the last 21 years Kathleen sold ZGNX stock worth over 386,087$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kathleen Schoemaker ZGNX stock SEC Form 4 insiders trading

Kathleen has made over 7 trades of the Zogenix Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Kathleen bought 285,714 units of ZGNX stock worth 3,999,996$ on 1 July 2013.

The largest trade Kathleen's ever made was buying 3,500,000 units of Zogenix Inc stock on 16 September 2011 worth over 7,000,000$. On average, Kathleen trades about 439,132 units every 141 days since 2004. As of 1 July 2013 Kathleen still owns at least 35,253 units of Zogenix Inc stock.

You can see the complete history of Kathleen Schoemaker stock trades at the bottom of the page.

What's Kathleen Schoemaker's mailing address?

Kathleen's mailing address filed with the SEC is C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE, PRINCETON, NJ, 08542.

Insiders trading at Zogenix Inc

Over the last 14 years, insiders at Zogenix Inc have traded over 5,100,850$ worth of Zogenix Inc stock and bought 57,764,538 units worth 193,451,745$ . The most active insiders traders include Advisors Llcperceptive Life...、Nicole Vitullo、Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of 13,059,406$. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth 15,000$.

What does Zogenix Inc do?

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Complete history of Kathleen Schoemaker stock trades at Alimera Sciences、Clovis Oncology Inc、Dicerna Pharmaceuticals Inc、Esperion Therapeutics、Evoke Pharma Inc、Nuvasive Inc、Tandem Diabetes Care Inc、Vanda Pharmaceuticals Inc、Veracyte Inc、Zogenix Inc

Zogenix Inc executives and stock owners

Zogenix Inc executives and other stock owners filed with the SEC include:

• Stephen Farr,
  President, Chief Executive Officer, Director
• Bradley Galer,
  Executive Vice President, Chief Medical Officer
• Michael Smith,
  Chief Financial Officer, Executive Vice President, Treasurer
• Gail Farfel,
  Executive Vice President, Chief Development Officer
• Ashish Sagrolikar,
  Executive Vice President, Chief Commercial Officer
• Dr. Stephen J. Farr,
  Co-Founder, CEO, Pres & Director
• Shawnte M. Mitchell,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Bradley S. Galer,
  Exec. VP & Chief Medical Officer
• Dr. Gail M. Farfel,
  Exec. VP & Chief Devel. Officer
• Michael P. Smith,
  Exec. VP, CFO & Treasurer
• Ashish M. Sagrolikar,
  Exec. VP & COO
• Cam Garner,
  Independent Chairman of the Board
• Erle Mast,
  Independent Director
• Louis Bock,
  Independent Director
• Mark Wiggins,
  Independent Director
• James Breitmeyer,
  Independent Director
• Renee Tannenbaum,
  Independent Director
• Denelle Waynick,
  Independent Director
• Mary Stutts,
  Independent Director
• Caroline Loewy,
  Independent Director
• Shawnte Mitchell,
  Executive Vice President, General Counsel, Secretary
• Stephen H. Jenner,
  VP of Marketing
• Bret E. Megargel,
  VP of Corp. Devel.
• Melinda Baker,
  Sr. Director of Corp. Communications
• Jeff D. Durflinger,
  VP of Technical Operations & Product Supply
• Ann D Rhoads,
  EVP, CFO, Treasurer & Sec.
• Thierry J.P. Darcis,
  EVP / General Manager, Europe
• Venture Partners Ii, Lp Sca...,
  
• Growth Partners Ii L P Chic...,
  
• Advisors Llcperceptive Life...,
  
• Roger Hawley,
  Chief Executive Officer
• James C Blair,
  Director
• Richard Scott Shively,
  Chief Commercial Officer
• Nicole Vitullo,
  10% owner
• Ken Haas,
  Director
• Cynthia Y Robinson,
  Chief Development Officer
• Brian K Halak,
  10% owner
• Arda Phd Minocherhomjee,
  Director
• Kurt Wheeler,
  Director
• Kathleen K Schoemaker,
  10% owner
• Lifesciences I, L.P.Clarus ...,
  
• Parters Vii L P Domain,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Venture Partners Ii, Lp Sca...,
  
• Brian H Dovey,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Jesse I Treu,
  10% owner
• Mcnerney & Partners Lp Thom...,
  
• Vii Associates Lp Dp,
  10% owner
• Lifesciences I, L.P.Clarus ...,